At the BIO USA in San Diego, USA

"China is already producing numerous candidate substances that have completed clinical proof-of-concept (PoC). Now is the golden time for Korea's bio industry to maintain its competitiveness."


Lee Seung-kyou, Vice Chairman of the Korea Biotechnology Industry Organization (KoreaBIO), made these remarks on June 22 (local time) during a press conference at the Korean Pavilion at the "2026 BIO International Convention (BIO USA)" held in San Diego, USA, referring to the ongoing restructuring of the global bio ecosystem. At the event, Lee identified the major themes of this year's convention as the U.S.-China supply chain bloc formation, the raising of standards in the investment and M&A markets, and the practical industrialization of artificial intelligence (AI) technology.

On the 22nd (local time), at the opening of the "2026 BIO International Convention (BIO USA)" held in San Diego, USA, Lee Seung-kyou (left), Vice Chairman of Korea Biotechnology Industry Organization (KoreaBIO), and Kim Rakgon, Director of KOTRA New York Trade Center, are speaking at a press conference. San Diego - Photo by Kwak Minjae

On the 22nd (local time), at the opening of the "2026 BIO International Convention (BIO USA)" held in San Diego, USA, Lee Seung-kyou (left), Vice Chairman of Korea Biotechnology Industry Organization (KoreaBIO), and Kim Rakgon, Director of KOTRA New York Trade Center, are speaking at a press conference. San Diego - Photo by Kwak Minjae

View original image

Vice Chairman Lee emphasized the need to keep a close watch on China's rapid growth in the global bio market. He stated, "The number of pipelines in China is now about three-quarters that of the United States," and explained, "More importantly, Chinese companies are expanding their technology exports because their pipelines have secured sufficient data for phase 2 clinical trials and beyond." He pointed out that when multinational pharmaceutical companies invest to secure pipelines, there is a growing trend of funds being directed toward Chinese firms with robust data.


In contrast, he assessed that Korean companies are at a relative disadvantage due to difficulties in securing funding. Lee said, "In Korea, we still have a large number of preclinical substances, and with recent investments nearly at a standstill, it has become extremely difficult to advance to clinical stages and achieve proof-of-concept." He added, "While large-scale phase 3 support funds are meaningful, to strengthen the ecosystem, it would be more effective to provide support that helps ventures quickly complete proof-of-concept by assisting with phase 2 clinical trials." He stressed the urgent need for small-scale funds to encourage startups and intensive support for early clinical development.


He also highlighted supply chain restructuring and the industrialization of new technologies as key topics of discussion. Lee said, "The invisible competition surrounding the U.S. and China supply chains is having a direct impact on the bio industry," and predicted, "In the contract development and manufacturing organization (CDMO) sector, the new competitive edge will be not only in terms of cost-effectiveness and safety, but also in the ability to deliver various therapeutic modalities simultaneously to the market." Regarding AI technology, he added, "Beyond mere possibilities or publicity, there will be concrete discussions on its actual deployment in industrial settings to improve clinical success rates and enhance cost-effectiveness."


Amidst this intersection of crisis and opportunity, the global standing of Korea's bio industry has reached new heights. At this year's BIO USA, a record-breaking integrated Korean Pavilion was organized, featuring 79 companies through the collaboration of eight institutions including the Korea Trade-Investment Promotion Agency (KOTRA).



Lee stated, "I can tangibly feel the elevated status of Korea's bio industry on the ground," and added, "For the first time in BIO USA's history, we have organized an official 'Korea Session' to discuss the growth of the Asian market in direct response to market demand." He continued, "With two domestic startups set to give presentations and special local lectures arranged for developing business development (BD) talent, we must seize this opportunity as multinational pharmaceutical companies are now turning their attention to Asia."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing